Category Archives: Uncategorized

Kraig Biocraft Laboratories poised to Close Out Yorkville Convertible Debenture with Strongest Financial Position in Corporate History

Ann Arbor, MI– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has nearly closed out its $8 million in convertible debenture with Yorkville Advisors. Over the last 23 months, the Company has converted more than 98% of this debt to equity. Kraig Labs remains in one of the strongest financial positions in the Company’s history, with more than $4.5 million in liquid assets and a remaining debt balance to Yorkville of only $150,000. 

The capital raised through this financing has been deployed in building out the Company’s in-house production and laboratory facilities in Vietnam, expanding the capabilities and research focus of our US-based R&D center, and funding the Company’s work with third-party production partners to scale up spider silk production. Looking forward, the Company expects to continue investing in the scale-up of production capacity, pioneering innovations in spider silk technologies, and bringing products to end markets through direct sales and strategic partnerships.

“Due to the significant progress that we made in securing our new production partnership program, which is designed to allow Kraig Labs to meet anticipated demand without the previous model’s intense capital investments, these funds provide us the flexibility that we need to continue to drive growth and strengthen our operations from R&D through finished products,” said Company COO, Jon Rice.

“With more than $4.5 million of immediately deployable capital and having nearly eliminated the balance on this debit financing, Kraig Labs has never been in a stronger financial position. We will continue to strategically invest this capital in ramping production through our in-house capacity and partnership with our third-party contractor as well as launch the next generations of hybrid spider silk technologies,” Rice concluded.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Enters Next Phase of Business Plan, Signs Deal with Contract Manufacturer to Produce Metric Tons of Recombinant Spider Silk

Ann Arbor, Michigan., – July 18, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the signing of its first 3rd party production contract for large scale manufacturing of the Company’s recombinant spider silk. The Company expects to immediately begin operations with this contractor producing hundreds of kilograms of spider silk per month and to achieve production levels reaching multiple metric tons of spider silk per month as early as the first quarter of 2023. The contractor is in possession of the Company’s specialized eggs and anticipates a 90-day ramp-up for the first deliveries under the contract.

Pilot testing with this contractor during the first two quarters of 2022 demonstrated the capacity and expertise of this manufacturer to operate at a large scale and with excellent quality.

Under the contract terms, Kraig Labs will become a minority owner of the silk producer. Kraig Labs will have complete access to the manufacturer’s financial records and an onsite presence to ensure the proper handling and security of the Company’s propriety spider silk technology.

“Our business model was designed to leverage the existing silk production infrastructure. The signing of this agreement rapidly expands our access into that production network and brings us to the next critical stage in our business plan,” said Company COO Jon Rice. “Working with this contract manufacturer, we will soon be ready to deliver metric tons of eco-responsible and cost-effective spider silk to the consumer markets.”

In the coming days, the Company plans to release the first in a series of behind-the-scenes videos looking into its operations in Vietnam and the commercialization of its spider silk materials.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Introduces New, Enhanced Line of Dragon Silk Silkworms for Commercial Production

Ann Arbor, MI – July 6, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has produced several new lines of larger hybrid Dragon SilkTM silkworms for its production operations in Vietnam. These new breeds of silkworms were explicitly created for large-scale production. 

With a larger cocoon and longer silk filament, these optimized Dragon Silk breeds reduce production costs and increase throughput.

The new breeds were created using a process of hybridization, combining the best properties of Dragon Silk with the best practices in silkworm breeding to improve the size and robustness of the silkworm strain. Commonly used in commercial mundane silk production, the process of creating these production hybrid silkworms delivers between 30-100% larger silk cocoons than non-hybridized silkworms.

The Company first began the development of large cocoon hybrids in 2018. The success of that effort is the foundation of today’s announcement and the rollout of this technology into production. Commercializing this technology required the Company to develop multiple strains of Dragon Silk hybrids that, when paired together, deliver a consistent and scalable large cocoon production platform.

“The hybridization program was a key part of the Company’s technology roadmap and something our R&D team has been quietly working on behind the scenes,” said Company COO Jon Rice. “Today, we announce that this technology is in the factory. This technology will lower our operating costs from rearing all the way through silk reeling and spinning. Over the coming months, our production team will transition egg production to this new, larger Dragon Silk line.”

Accelerating the transition of these new larger breeds of Dragon Silk to production was driven by the Company’s success with 3rd party contract production and our rapidly growing demand for increased quantities of Dragon Silk.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Enters Biomedical Field with First Sample Shipments of Fibers and Fabrics for Tissue Engineering

ANN ARBOR, Mich., – May 17, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the first sample shipment of its recombinant spider silk fibers and fabrics for use and evaluation into a range of biomedical applications. This shipment was made in response to the significant increase in the requests for its propriety spider silk technology over the last two quarters for tissue engineering applications.

Aided by its unique blend of mechanical and chemical properties, spider silk has long been recognized as an ideal natural biomaterial. As a lightweight, biocompatible, and biodegradable material, spider silk applications have been tested in numerous morphologies, including; fibers, films, hydrogels, non-woven fabrics, foams, etc. While the first known uses of spider silk as a suture date back to the 18th century, limitations in the production and costs of spider silk have prevented its broad adoption.

Kraig Labs’ revolutionary approach creating recombinant spider silk technology utilizing genetically enhanced silkworms unlocks the door for large-scale adoption of spider silk for biomedical applications. This system merges the performance of spider silk with the well-established, large-scale supply chain for mundane silk.

With the growth of its production operations in Vietnam over the last two quarters, the Company is now positioned to allot a portion of its spider silk production to address the medical community’s needs. This week’s shipments are just the first in what the Company hopes will be a significant mid to long-term market growth opportunity for Kraig Labs and its foray into the growing field of bioengineering.

“Over the last month, we have seen a significant increase in the demand from the medical field for our spider silk fibers and fabrics,” said COO Jon Rice. “With the great work our team in Vietnam has done increasing monthly silk production, we are now positioned to begin supplying R&D samples for this new and exciting end market. As these applications often require FDA approval, we believe the biomedical space has the potential to play an important role in the long-term growth of the Company. Over the coming months we will be closely monitoring the results of these first tests and assessing additional opportunities for the spider silk gels and films we have already developed into the broad field of biomaterials.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Strengthens Q2 Spider Silk Production Expansion with New Vendor Quality Assurance Program

ANN ARBOR, Mich., – May 3, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has strengthened its second-quarter production expansion with a new vendor quality assurance program. This new program will allow the Company to screen numerous mulberry suppliers and grow its database of trusted vendors. 

This new vendor verification program was put in place to address the Company’s growing demand for high-quality mulberry as a feedstock for its expanding production of recombinant spider silk. As the primary raw input for the Company’s spider silk production, growing its supply base of verified mulberry producers is a crucial component for the continued production expansion. 

Equipment and processes refined in the first quarter have positioned the Company to focus nearly all of this quarter’s operations on finished yarn production. 85% of all silkworms produced this month are slated for spinning and use in finished fabrics and garments. These materials will be dedicated to the Company’s joint venture apparel brand, SpydasilkTM. The remaining 15% of production will be devoted to the Company’s regenerative breeding program and growing the production base for the third quarter and beyond. 

The relationship between nutrition and high-quality silk production cannot be overstated. Nutritional management is one the most important factors in maintaining optimal colony productivity and wellbeing. This new vendor verification process will play an essential role as the Company looks to the future and outgrowing its existing production footprint and supplier base.

“Prodigy Textiles is experiencing intensive growth,” said Company COO, Jon Rice. “Putting systems in place to ensure that we are able to sustain Dragon Silk’s™ record-setting performance levels is key to managing that growth and delivering cost-effective and eco-responsible spider silk. This new supplier verification process will give us the confidence to aggressively pursue the growth needed, by increasing feed efficiency and maintaining feed quality, to fulfill material demand for months and years to come.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Leading Experts

Company Founder and Chief Executive Officer: Kim K. Thompson

Mr. Thompson received his B.A. in Applied Economics from James Madison College at Michigan State University. He received his Juris Doctorate from the University of Michigan Law School.

Kim Thompson invented the spider silk production platform and founded Kraig Biocraft Laboratories in his pursuit of the development of new biotechnologies with industrial applications.  The Company was founded to develop this spider silk technology and reduce it to practice in collaboration with leading university scientists.

Mr. Thompson brings a wealth of experience in business management and consultation to Kraig. Following the completion of his undergraduate degree, Mr. Thompson joined California Craftsman, Inc. as a Vice-President with primary responsibility for both financial operations and marketing.

Kim Thompson was the director of business development at Franchise Venture Partners, LLC. He subsequently joined the firm of Shearson, Lehman, Hutton where he specialized in equity trading and research of small-cap companies. His experience in those small-cap equity markets has proven to be invaluable both in his legal and business successes.

Prior to founding Kraig, Mr. Thompson was the founder and senior litigation partner in a successful California commercial law firm where he worked as corporate and litigation counsel to privately held and public companies. His many accomplishments in corporate law include winning and collecting in full what his firm believes to have been the largest award of lost profits in a California commercial arbitration up to that time. An important part of his work was winning victories on behalf of corporate clients in disputes over intellectual property and distribution rights. He has represented business clients ranging from small start-ups and micro-caps to Fortune 100 companies.

With a background in business leadership and in advising public and private corporations, Kim Thompson continues to bring a unique perspective to the successful management of the Company. His extensive business and legal background enables him to create practical solutions to business problems and seize opportunities for growth.

Mr. Thompson is a member of the Triple Nine Society for persons with documented genius level IQs (having tested above the 99.9th percentile). He is active in the realm of science and invention where he has to his credit a number of provisional patent applications, including innovations in the areas of biotechnology, organic polymers, genetic engineering and magnetic field manipulation, among others.

Chief Operations Officer: Jon R. Rice

Mr. Rice has over 13 years’ experience growing development stage businesses with a focus on technology development, commercialization, and go to market strategies.  Mr. Rice holds a B.S. in Chemical engineering from Michigan Technological University and a Masters of Business Administration from the Eli Broad College of Business: Michigan State University.

Prior to joining Kraig Biocraft Laboratories Mr. Rice was the Director of Advanced Technologies for Ultra Electronics, AMI.  In this role, Mr. Rice was responsible for the identification, capture, and execution of new technology programs.  During his tenure with AMI, Rice secured more than twenty five million dollars in funded development programs from the US Department of Defense which his team successfully leveraged into commercially viable spinoff products.  Mr. Rice was also responsible for technical sales, marketing, and promotion of AMI’s products and capabilities.   Rice joined AMI as the third full time employee and helped to lead the organization through its rapid growth and ultimate acquisition by Ultra Electronics in 2011.

Earlier in his career Mr. Rice developed unique advanced manufacturing techniques, established and trained a production staff, led engineering development, authored numerous technical papers, and is a recognized subject matter expert.  Mr. Rice holds 5 issued patents and numerous provisional patents.

Mr. Rice brings a history of transforming revolutionary ideas into viable commercial products.

Kraig Biocraft Laboratories Mission Statement

Kraig Biocraft Laboratories is an innovative biotechnology company that is applying cutting edge technology to the creation and development of high-performance fibers. A primary focus of our work is the development and commercialization of genetically engineered recombinant spider silk. The Company believes that this technology is revolutionary in terms of its potential to impact the markets for industrial, consumer and military materials. Our work is based on proprietary genetic engineering technology and a model of environmental sustainability. Combining human ingenuity with the bounty of nature will help to expand the realms of high-tech with never before seen materials. Accordingly, our mission consists of 3 unified parts:

Technological Mission:

To develop and commercialize new types of protein-based fibers that will improve consumer, industrial and defense industry product lines, as well as craft entirely new product possibilities. Our first and second generation spider silk technologies, which we call Monster Silk™ and Dragon Silk™, respectively, have been in pilot production and are moving toward commercial scale production. Initial target markets include the apparel markets, while our future vision for our silks includes industrial uses and lifesaving technologies, ranging from anti-ballistic applications to medical breakthroughs. To materialize our vision, we must strive for the highest possible quality in our products and ensure that our research arm remains focused on continuing our history of laboratory breakthroughs.

Social Mission:

To remain focused on improving our world; the original motivation for pursuing the creation of transgenic recombinant spider silk and founding the Company. We view ourselves as partners with our environment, as well as responsible guardians of our natural resources, and, by working with nature, we believe that we can replace toxic technologies that hurt our environment with natural and ethical production methods that also yield improved materials.

Financial Mission:

To maximize shareholder and enterprise value. There are three focus areas which are key to achieving our financial mission:

1) Moving our Monster Silk™ and Dragon Silk™ (recombinant spider silk) technology into commercial scale production and commercialization;

2) Become a globally recognized brand name by capitalizing on the vast interest in spider silk technologies, and;

3) Continue to develop new advanced spider silk based fibers which can capture larger and larger portions of the technical textile market.

We will continue to advance the Company’s spider silk vanguard position, by focusing on our biotech engineering core competencies. We will be the providers of material science products and strategies that deliver long term commercial benefits, based upon our clients’ needs. We have confidence that as we deliver on all dimensions of our viable mission plan and seize market opportunities, we will enjoy the kind of success that is reflected in enterprise value.

Kraig Labs believes that the most powerful fibers and polymers on earth can also be the cleanest and by valuing Kraig’s three mission segments we will build on our successes both in the short and long term. We know that we can advance our objectives by supporting inquisitive, skilled, and caring young people (and some who are not so young) who share our vision to help create a better world. We can do that through sustainable technologies, as well as serving as an important gathering point for innovative and creative minds.